KRAS and metastatic colorectal cancer: Contrastingly, mOS decreased by approximately 2 months in patients with other KRAS mutations, once cetuximab was added to the regimen, thus indicating KRAS G13D conferred the most favourable prognosis in metastatic colorectal cancer patients treated with cetuximab and chemotherapy (Tejpar et al., 2012).